An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

NCT05199610 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hepatic Impairment

Interventions

DRUG: aumolertinib

Sponsor

EQRx International, Inc.